Loading stock data…
TFC
$50.93-0.57 (-1.11%)
Market ClosedLast close May 1
Truist Financial Corporation, a financial services company, provides banking and trust services in the Southeastern and Mid-Atlantic United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Truist Financial Corporation in the Financial Services sector is trading at $50.93. The stock is currently 9% below its 52-week high of $56.20, remaining 9.2% above its 200-day moving average. Technical signals show neutral RSI of 58 and bullish MACD crossover, explaining why TFC maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 58) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JPMBACGS
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$50.93
Potential Upside
55.4%
Whystock Fair Value$79.16
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus19 analysts
Buy
Mean target$55.53+9.0%
Range$45.00 – $63.00
Fundamentals
Truist Financial Corporation, a financial services company, provides banking and trust services in the Southeastern and Mid-Atlantic United States. The company operates through two segments, Consumer and Small Business Banking; and Wholesale Banking....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$63.48B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
12.61
Beta
Defensive asset. Lower volatility than the S&P 500.
0.87
Div Yield
Strong income play. Yield provides a meaningful total return floor.
408.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.01%
Volume
Today's trading volume
4.85M
Recent News
Why Element Solutions (ESI) Is Riding A Powerful Industry Wave
With year-to-date performance of 65.92% as of April 30 2026, Element Solutions Inc (NYSE:ESI) is among the 10 Under-the-Radar Stocks That Are On Fire Right Now. Element Solutions Inc (NYSE:ESI) has drawn fresh analyst support after posting strong quarterly results, reinforcing the company’s standing as a key supplier to electronics and semiconductor manufacturing markets. On April 30, […]
What Analysts Think About Genius Sports Limited (GENI)
Genius Sports Limited (NYSE:GENI) is among the best fundamentally strong penny stocks to invest in now. On April 21, Truist cut the price target on Genius Sports Limited (NYSE:GENI) to $10 from $13 and reiterated a Buy rating. This re-rating is part of a broader research note. According to the firm, the sector lags in […]
Is MannKind Corporation (MNKD) The Best Fundamentally Strong Penny Stock to Invest In Now?
MannKind Corporation (NASDAQ:MNKD) is among the best fundamentally strong penny stocks to invest in now. On April 8, TheFly reported that Truist trimmed the price target on MannKind Corporation (NASDAQ:MNKD) to $6 from $7 and reiterated a Buy rating. This downward revision in price was a part of a broader research note previewing Q1 earnings […]
Truist Reaffirms Buy on Eli Lilly (LLY) After Trial Success
Eli Lilly & Company (NYSE:LLY) ranks among the stocks to invest in before they split next. Truist Securities restated its Buy rating and $1,281 price target for Eli Lilly & Company (NYSE:LLY) shares on April 17, following encouraging Phase 3 trial outcomes for Foundayo in type 2 diabetes. Eli Lilly & Company (NYSE:LLY) reported the […]
How The Investment Narrative For XPO (XPO) Is Shifting With New Targets And Assumptions
XPO’s refreshed fair value estimate has moved from US$207.04 to US$219.61, putting more attention on how new price targets stack up against where the stock trades today. Recent commentary from banks such as JPMorgan and Goldman Sachs, alongside other research that ranges from upbeat to more cautious, feeds directly into this higher fair value number and the broader cluster of targets around the low US$200s. As you read on, you will see how to interpret these shifting targets and follow the...